- Recruiting
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
Updated: Sep 16, 2022
Talquetamab Phase 1b study
NCT05050097: phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
Sponsor
Multiple locations
International Study
ClinicalTrials.gov Identifier: NCT05050097
Official Title: A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
First Posted : September 20, 2021
Click here to see details on ClinicalTrials.gov
Treatment Regimen A: Talquetamab + Carfilzomib
Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib
Treatment Regimen C: Talquetamab + Lenalidomide
Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide
Treatment Regimen E: Talquetamab + Pomalidomide
Drug: Talquetamab (SC)
bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D)
JNJ 64407564
Drug: Carfilzomib ( Kyprolis)
Drug: Daratumumab SC ( DARZALEX FASPRO)
Drug: Lenalidomide (Revlimid)
Drug: Pomalidomide (Pomalyst)
- Multiple locations
- International study
- Alabama: University of Alabama at Birmingham
- California: University of California San Francisco
- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver
- Georgia: Emory University Atlanta
- Indiana: Indiana University Indianapolis
- New Jersey: Hackensack University Medical Center
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
- New York: New York Presbyterian / Weill Cornell Medical College New York
- North Carolina: Levine Cancer Institute Charlotte
- Pennsylvania: University of Pittsburgh Medical Center
- Tennessee: Sarah Cannon Research Institute Nashville
- Wisconsin: Medical College Of Wisconsin Milwaukee
Locations
United States, Alabama
United States, California
United States, Colorado
United States, Georgia
United States, Indiana
United States, New Jersey
United States, New York
United States, North Carolina
United States, Pennsylvania
United States, Tennessee
United States, Wisconsin
Europe
United Kingdom
France
Netherlands
Belgium
Australia
RELATED POSTS
TECLISTAMAB STUDIES:
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)
NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)
CT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
TALQUETAMAB STUDIES:
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
TECLISTAMAB AND TALQUETAMAB STUDIES:
NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2